Tolremo Therapeutics
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.
7-day free trial · no credit card
Verified contacts
9
available on Kipplo
LinkedIn employees
15
11 to 50 range
Open roles
—
no listings
Distinct roles
6
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 9 verified contacts at Tolremo Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
9 contacts with verified email or phone · masked until revealed.
- IN
Ingrid Nichiforel
Office Manager · Operations
EmailPhone - DG
Dorothea Gruber
Operations Manager, Clinical Sciences · Other
EmailPhone
Showing 2 of 9 verified contacts
Top roles at Tolremo Therapeutics
6 distinct titles indexed · top 6 shown.
- 2ceo and co-founder
- 1ceo and co-founder | phd in translational biomedicine
- 1chief operating officer
- 1member, scientific advisory board
- 1office manager
- 1operations manager, clinical sciences
Sign up to unlock all 9 contacts at Tolremo Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 9 verified contacts at Tolremo Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.